# Global Medical Strategy Use Cases
## Evidence-Based Decision Making & Advanced Analytics

**Version:** 1.0
**Date:** December 2024
**Target Audience:** Global Medical Strategy Teams
**Classification:** Client Engagement Methodology

---

## Executive Summary

This document provides a comprehensive framework for leveraging the VITAL platform to enable **evidence-based decision making** and **advanced insight generation** for Global Medical Strategy teams. It bridges the gap between scattered evidence sources and high-stakes strategic decisions through AI-powered synthesis, quantified value drivers, and persona-adapted experiences.

---

## Table of Contents

1. [The Strategic Challenge](#1-the-strategic-challenge)
2. [VITAL Platform Capabilities](#2-vital-platform-capabilities)
3. [Core Use Cases](#3-core-use-cases)
4. [Evidence-Based Decision Framework](#4-evidence-based-decision-framework)
5. [Advanced Analytics & Insights](#5-advanced-analytics--insights)
6. [Value Quantification](#6-value-quantification)
7. [Implementation Playbook](#7-implementation-playbook)
8. [Success Metrics](#8-success-metrics)

---

## 1. The Strategic Challenge

### The Decision-Evidence Gap

Global Medical Strategy teams face a fundamental challenge: synthesizing complex, multi-source evidence to make high-stakes decisions under time pressure.

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                         THE DECISION-EVIDENCE GAP                            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                             â”‚
â”‚    EVIDENCE SOURCES                              STRATEGIC DECISIONS        â”‚
â”‚    â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                             â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€         â”‚
â”‚    â€¢ Clinical trial data                         â€¢ Therapeutic area         â”‚
â”‚    â€¢ Real-world evidence                           prioritization           â”‚
â”‚    â€¢ Competitive intelligence                    â€¢ Resource allocation      â”‚
â”‚    â€¢ KOL insights                                â€¢ Market positioning       â”‚
â”‚    â€¢ Regulatory landscape                        â€¢ Evidence generation      â”‚
â”‚    â€¢ Market access data                            strategy                 â”‚
â”‚    â€¢ HEOR analyses                               â€¢ Launch sequencing        â”‚
â”‚    â€¢ Publication trends                          â€¢ Portfolio decisions      â”‚
â”‚                                                                             â”‚
â”‚                          â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                               â”‚
â”‚                          â”‚  TIME PRESSURE   â”‚                               â”‚
â”‚                          â”‚  SILOS           â”‚                               â”‚
â”‚                          â”‚  COGNITIVE LOAD  â”‚                               â”‚
â”‚                          â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                               â”‚
â”‚                                                                             â”‚
â”‚    KEY PAIN POINTS:                                                         â”‚
â”‚    â€¢ Average time to synthesize evidence for strategic decision: 2 weeks   â”‚
â”‚    â€¢ Decisions made without complete evidence: 60%                          â”‚
â”‚    â€¢ Cost of delayed decisions: $2M+ per week                               â”‚
â”‚    â€¢ Cross-functional alignment meetings: 8-12 per major decision          â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### The Value Proposition

VITAL transforms this challenge by providing:

1. **Ontology-Anchored Discovery** - Every insight maps to your organizational structure
2. **Multi-Source Evidence Synthesis** - AI-powered aggregation from clinical, market, and competitive sources
3. **Quantified Prioritization** - Value drivers with measurable business outcomes
4. **Persona-Adapted Experiences** - Tailored AI interactions for different strategic roles

---

## 2. VITAL Platform Capabilities

### 2.1 Enterprise Ontology (L0-L7)

The platform is built on a comprehensive knowledge graph:

| Layer | Entity | Current Count | Medical Strategy Relevance |
|-------|--------|---------------|---------------------------|
| L0 | Therapeutic Areas | 15 | Filter by TA focus |
| L0 | Diseases | 72 | Disease-specific insights |
| L0 | Evidence Types | 11 | Evidence hierarchy (1aâ†’5) |
| L0 | Regulatory Frameworks | 26 | Global regulatory landscape |
| L1 | Functions | 27 | Cross-functional intelligence |
| L2 | Departments | 149 | Strategic touchpoints |
| L3 | Roles | 949 | Stakeholder mapping |
| L4 | Personas | 1,798 | User archetypes (4 per role) |
| L5 | JTBDs | 461 | Jobs-to-be-done mapping |
| L6 | Value Driver Mappings | 2,520 | Business outcome linkage |
| L7 | AI Agents | 972 | Specialized expert systems |

### 2.2 GraphRAG Intelligence Broker

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                     INTELLIGENCE BROKER                              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚  Query Analysis â†’ Strategy Selection â†’ Multi-Modal Retrieval        â”‚
â”‚                                                                      â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”              â”‚
â”‚  â”‚ Neo4j Graph  â”‚  â”‚ Pinecone     â”‚  â”‚ PostgreSQL   â”‚              â”‚
â”‚  â”‚ (Ontology)   â”‚  â”‚ (Vectors)    â”‚  â”‚ (Structured) â”‚              â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜              â”‚
â”‚         â†“                 â†“                 â†“                       â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”           â”‚
â”‚  â”‚        Reciprocal Rank Fusion (RRF)                  â”‚           â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜           â”‚
â”‚                           â†“                                         â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”           â”‚
â”‚  â”‚        Unified Context + Evidence Response           â”‚           â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Features:**
- Query complexity analysis (SIMPLE â†’ MODERATE â†’ COMPLEX â†’ REGULATORY)
- 11 pre-configured retrieval strategies
- L0-L7 ontology traversal via Neo4j
- Multi-namespace vector search (20+ specialized namespaces)
- Service mode optimization (Ask Me, Ask Expert, Ask Panel, Workflows)

### 2.3 Value Framework (66 Hierarchical Drivers)

```
VD-ROOT-001: Sustainable Business
â”œâ”€â”€ VD-REV-001: Revenue Growth
â”‚   â”œâ”€â”€ VD-REV-010: Increase Volume
â”‚   â”‚   â”œâ”€â”€ VD-REV-011: Increase Market Size
â”‚   â”‚   â”œâ”€â”€ VD-REV-012: Increase Market Share
â”‚   â”‚   â””â”€â”€ VD-REV-013: Increase Length of Therapy
â”‚   â””â”€â”€ VD-REV-020: Increase Product Value
â”‚       â”œâ”€â”€ VD-REV-021: Build Product Value Story
â”‚       â””â”€â”€ VD-REV-022: Offer Additional Services
â”œâ”€â”€ VD-CST-001: Cost Savings
â”‚   â”œâ”€â”€ VD-CST-010: Medical Ops Efficiency
â”‚   â”œâ”€â”€ VD-CST-020: Commercial Ops Efficiency
â”‚   â”œâ”€â”€ VD-CST-030: Business Ops Efficiency
â”‚   â””â”€â”€ VD-CST-040: IT Ops Efficiency
â””â”€â”€ VD-RSK-001: Risk Reduction
    â”œâ”€â”€ VD-RSK-010: Regulatory Risks
    â”œâ”€â”€ VD-RSK-020: Market Risks
    â””â”€â”€ VD-RSK-030: Operational Risks
```

---

## 3. Core Use Cases

### Use Case 1: Therapeutic Area Prioritization

**Scenario:** Global Medical Strategy must prioritize therapeutic areas for resource allocation.

**Current State:**
- 4-6 weeks of data gathering
- 8-12 cross-functional alignment meetings
- Subjective prioritization criteria
- Incomplete competitive landscape view

**VITAL-Enabled State:**

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  THERAPEUTIC AREA PRIORITIZATION WORKFLOW                                    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                             â”‚
â”‚  STEP 1: Evidence Synthesis (AI-Powered)                                    â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                   â”‚
â”‚  Query: "Compare oncology vs. immunology investment potential based on      â”‚
â”‚          pipeline maturity, competitive landscape, and market access"       â”‚
â”‚                                                                             â”‚
â”‚  Sources Integrated:                                                        â”‚
â”‚  â€¢ Clinical trial databases (phases, endpoints, comparators)                â”‚
â”‚  â€¢ Competitive intelligence (pipeline, approvals, market share)             â”‚
â”‚  â€¢ HEOR studies (cost-effectiveness, budget impact)                         â”‚
â”‚  â€¢ Regulatory landscape (FDA/EMA guidance, precedents)                      â”‚
â”‚  â€¢ KOL network mapping (influence, expertise areas)                         â”‚
â”‚                                                                             â”‚
â”‚  STEP 2: Strategic Opportunity Matrix                                       â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                      â”‚
â”‚                                                                             â”‚
â”‚              LOW          AI SUITABILITY          HIGH                      â”‚
â”‚                â”‚                â”‚                   â”‚                       â”‚
â”‚           HIGH â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤                       â”‚
â”‚                â”‚                â”‚                   â”‚                       â”‚
â”‚                â”‚  Oncology L3   â”‚   Immunology L2   â”‚                       â”‚
â”‚     VALUE      â”‚  (Strategic    â”‚   (Quick Win)     â”‚                       â”‚
â”‚     IMPACT     â”‚   Investment)  â”‚   â˜… Priority â˜…    â”‚                       â”‚
â”‚                â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤                       â”‚
â”‚                â”‚                â”‚                   â”‚                       â”‚
â”‚                â”‚  CNS Pipeline  â”‚   Rare Disease    â”‚                       â”‚
â”‚           LOW  â”‚  (Deprioritize)â”‚   (Efficiency)    â”‚                       â”‚
â”‚                â”‚                â”‚                   â”‚                       â”‚
â”‚                â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                       â”‚
â”‚                                                                             â”‚
â”‚  STEP 3: Value Quantification                                               â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                           â”‚
â”‚  Each TA mapped to value drivers:                                           â”‚
â”‚  â€¢ VD-REV-012 (Market Share): Immunology = $2.5B potential                  â”‚
â”‚  â€¢ VD-RSK-010 (Regulatory): Oncology = High complexity                      â”‚
â”‚  â€¢ VD-CST-010 (Medical Ops): Rare Disease = Lower cost                      â”‚
â”‚                                                                             â”‚
â”‚  DELIVERABLE: Prioritized TA Portfolio with ROI projections                 â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Value Delivered:**
- Time reduction: 4-6 weeks â†’ 3-5 days (85% faster)
- Evidence completeness: 60% â†’ 95%
- Cross-functional alignment: 8 meetings â†’ 2 meetings
- Quantified business case for each TA

---

### Use Case 2: Evidence Gap Analysis

**Scenario:** Identify gaps in evidence portfolio for strategic planning.

**VITAL Capability:** Multi-dimensional evidence mapping across clinical, regulatory, and market access dimensions.

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  EVIDENCE GAP ANALYSIS DASHBOARD                                             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                             â”‚
â”‚  EVIDENCE HIERARCHY (Per Indication)                                        â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                        â”‚
â”‚                                                                             â”‚
â”‚  Level    Type                    Product A    Product B    Gap Score       â”‚
â”‚  â”€â”€â”€â”€â”€    â”€â”€â”€â”€                    â”€â”€â”€â”€â”€â”€â”€â”€â”€    â”€â”€â”€â”€â”€â”€â”€â”€â”€    â”€â”€â”€â”€â”€â”€â”€â”€â”€       â”‚
â”‚  1a       Systematic Review/MA    âœ… Complete   âš ï¸ Partial   Medium          â”‚
â”‚  1b       Randomized Trial        âœ… Complete   âœ… Complete   Low             â”‚
â”‚  2a       Cohort Studies          âš ï¸ Partial   âŒ Missing    High            â”‚
â”‚  2b       RWE/PRO Data            âŒ Missing    âŒ Missing    Critical        â”‚
â”‚  3        Case-Control            âœ… Complete   âš ï¸ Partial   Low             â”‚
â”‚                                                                             â”‚
â”‚  EVIDENCE DIMENSIONS                                                        â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                                        â”‚
â”‚                                                                             â”‚
â”‚                Clinical    Regulatory    Market Access    Competitive       â”‚
â”‚  Product A     â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ    â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘â–‘â–‘    â–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘     â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ     â”‚
â”‚  Product B     â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ    â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘    â–ˆâ–ˆâ–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘     â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘â–‘â–‘â–‘â–‘     â”‚
â”‚  Product C     â–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘â–‘â–‘    â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ    â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ     â–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘     â”‚
â”‚                                                                             â”‚
â”‚  PRIORITY GAPS (AI-Identified)                                              â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                              â”‚
â”‚  1. RWE data for Product A in elderly population (Impact: $50M value)       â”‚
â”‚  2. Head-to-head data vs. competitor X (Impact: Payer negotiations)         â”‚
â”‚  3. Long-term safety data for Product B (Impact: Label expansion)           â”‚
â”‚                                                                             â”‚
â”‚  RECOMMENDED ACTIONS (Linked to Value Drivers)                              â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                              â”‚
â”‚  â€¢ Commission RWE study â†’ VD-REV-021 (Value Story): +$2.5M annual value     â”‚
â”‚  â€¢ Initiate head-to-head trial â†’ VD-REV-012 (Market Share): +3% share       â”‚
â”‚  â€¢ Extend registry follow-up â†’ VD-RSK-010 (Regulatory): Risk mitigation     â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

### Use Case 3: Competitive Intelligence Synthesis

**Scenario:** Real-time competitive landscape monitoring and strategic response.

**VITAL Capability:** AI-powered synthesis from multiple intelligence sources with proactive alerting.

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  COMPETITIVE INTELLIGENCE HUB                                                â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                             â”‚
â”‚  REAL-TIME COMPETITIVE ALERTS                                               â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                               â”‚
â”‚                                                                             â”‚
â”‚  ğŸ”´ HIGH PRIORITY (Last 24h)                                                â”‚
â”‚  â”œâ”€â”€ Competitor X: Phase 3 results announced (ASCO)                         â”‚
â”‚  â”‚   â””â”€â”€ AI Analysis: Superior PFS in subgroup, threat to Product A        â”‚
â”‚  â”‚       Recommended Response: Expedite RWE publication                     â”‚
â”‚  â”‚                                                                          â”‚
â”‚  â”œâ”€â”€ Competitor Y: FDA breakthrough designation                             â”‚
â”‚  â”‚   â””â”€â”€ AI Analysis: Accelerated timeline by 18 months                     â”‚
â”‚  â”‚       Recommended Response: Re-evaluate launch sequencing                â”‚
â”‚  â”‚                                                                          â”‚
â”‚  ğŸŸ¡ MEDIUM PRIORITY (Last 7d)                                               â”‚
â”‚  â”œâ”€â”€ Competitor Z: New pricing strategy in Germany                          â”‚
â”‚  â””â”€â”€ Competitor W: KOL shift detected (3 tier-1 KOLs joined advisory)       â”‚
â”‚                                                                             â”‚
â”‚  COMPETITIVE POSITION MAP                                                   â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                                    â”‚
â”‚                                                                             â”‚
â”‚                    Efficacy                                                 â”‚
â”‚                    â–²                                                        â”‚
â”‚               HIGH â”‚    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”                                          â”‚
â”‚                    â”‚    â”‚Product â”‚    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”                            â”‚
â”‚                    â”‚    â”‚   A    â”‚    â”‚Comp X  â”‚                            â”‚
â”‚                    â”‚    â””â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â””â”€â”€â”€â”€â”€â”€â”€â”€â”˜                            â”‚
â”‚                    â”‚                                                        â”‚
â”‚                    â”‚         â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”                                     â”‚
â”‚                    â”‚         â”‚Comp Y  â”‚                                     â”‚
â”‚                    â”‚         â””â”€â”€â”€â”€â”€â”€â”€â”€â”˜                                     â”‚
â”‚               LOW  â”‚â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â–º Safety                â”‚
â”‚                         LOW              HIGH                               â”‚
â”‚                                                                             â”‚
â”‚  STRATEGIC RESPONSE OPTIONS (AI-Generated)                                  â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                  â”‚
â”‚  Option 1: Accelerate subgroup analysis publication (4 weeks)               â”‚
â”‚  Option 2: Initiate head-to-head study design (6 months)                    â”‚
â”‚  Option 3: Expand RWE collaboration network (immediate)                     â”‚
â”‚                                                                             â”‚
â”‚  Each option mapped to: JTBDs, Value Drivers, Resource Requirements         â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

### Use Case 4: KOL Network Intelligence

**Scenario:** Optimize KOL engagement strategy based on influence and expertise mapping.

**VITAL Capability:** Graph-based relationship analysis with AI-powered insight synthesis.

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  KOL NETWORK INTELLIGENCE                                                    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                             â”‚
â”‚  INFLUENCE NETWORK VISUALIZATION                                            â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                             â”‚
â”‚                                                                             â”‚
â”‚             â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”             â”‚
â”‚             â”‚                                                 â”‚             â”‚
â”‚             â”‚     â—â”€â”€â”€â”€â”€â—         â—â”€â”€â”€â—                       â”‚             â”‚
â”‚             â”‚    /â”‚\     \       / \   \                      â”‚             â”‚
â”‚             â”‚   â— â— â—     â—â”€â”€â”€â”€â”€â—   â—   â—                     â”‚             â”‚
â”‚             â”‚   â”‚ â”‚ â”‚     â”‚     â”‚   â”‚   â”‚                     â”‚             â”‚
â”‚             â”‚   â— â— â—     â—     â—   â—   â—                     â”‚             â”‚
â”‚             â”‚                                                 â”‚             â”‚
â”‚             â”‚   Cluster A         Cluster B                   â”‚             â”‚
â”‚             â”‚   (Academic)        (Clinical Practice)         â”‚             â”‚
â”‚             â”‚                                                 â”‚             â”‚
â”‚             â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜             â”‚
â”‚                                                                             â”‚
â”‚  TOP KOL INSIGHTS                                                           â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                                            â”‚
â”‚                                                                             â”‚
â”‚  Name               Influence    Expertise       Engagement    Gap          â”‚
â”‚  â”€â”€â”€â”€               â”€â”€â”€â”€â”€â”€â”€â”€â”€    â”€â”€â”€â”€â”€â”€â”€â”€â”€       â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€    â”€â”€â”€          â”‚
â”‚  Dr. Sarah Chen     Tier 1       Oncology, IO    Strong        -            â”‚
â”‚  Prof. James Liu    Tier 1       Cardiology      Medium        âš ï¸ Under-    â”‚
â”‚  Dr. Maria Lopez    Tier 2       Rare Disease    Weak          âŒ No        â”‚
â”‚                                                                contact      â”‚
â”‚                                                                             â”‚
â”‚  AI-GENERATED ENGAGEMENT RECOMMENDATIONS                                    â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                     â”‚
â”‚  1. Prof. James Liu: Invite to upcoming advisory board (cardiology focus)   â”‚
â”‚     â””â”€â”€ Linked to JTBD: "Build KOL relationships" (MA-JTBD-015)             â”‚
â”‚     â””â”€â”€ Value Driver: VD-REV-124 (HCP Loyalty) - Impact: +$500K/year        â”‚
â”‚                                                                             â”‚
â”‚  2. Dr. Maria Lopez: Initiate research collaboration (rare disease)         â”‚
â”‚     â””â”€â”€ Linked to JTBD: "Generate real-world evidence" (MA-JTBD-042)        â”‚
â”‚     â””â”€â”€ Value Driver: VD-REV-021 (Value Story) - Impact: +$1.2M/year        â”‚
â”‚                                                                             â”‚
â”‚  NETWORK HEALTH METRICS                                                     â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                                      â”‚
â”‚  â€¢ Coverage Score: 78% (Tier 1), 45% (Tier 2), 23% (Tier 3)                 â”‚
â”‚  â€¢ Engagement Trend: â†‘ 12% YoY                                              â”‚
â”‚  â€¢ Competitive Risk: 3 Tier-1 KOLs recently engaged by Competitor X         â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

### Use Case 5: Publication Strategy Optimization

**Scenario:** Optimize publication planning based on evidence gaps and competitive timing.

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  PUBLICATION STRATEGY OPTIMIZER                                              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                             â”‚
â”‚  PUBLICATION PIPELINE OVERVIEW                                              â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                              â”‚
â”‚                                                                             â”‚
â”‚  Status        Q1 2025    Q2 2025    Q3 2025    Q4 2025                     â”‚
â”‚  â”€â”€â”€â”€â”€â”€        â”€â”€â”€â”€â”€â”€â”€    â”€â”€â”€â”€â”€â”€â”€    â”€â”€â”€â”€â”€â”€â”€    â”€â”€â”€â”€â”€â”€â”€                     â”‚
â”‚  Planned       â–ˆâ–ˆâ–ˆâ–ˆ 4     â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ 6   â–ˆâ–ˆâ–ˆâ–ˆ 4     â–ˆâ–ˆ 2                        â”‚
â”‚  In Progress   â–ˆâ–ˆ 2       â–ˆâ–ˆâ–ˆâ–ˆ 4     â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ 6   â–ˆâ–ˆâ–ˆâ–ˆ 4                      â”‚
â”‚  Published     â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ 8 â–ˆâ–ˆ 2       -          -                           â”‚
â”‚                                                                             â”‚
â”‚  AI-OPTIMIZED PUBLICATION RECOMMENDATIONS                                   â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                     â”‚
â”‚                                                                             â”‚
â”‚  Priority 1: Subgroup Analysis (OS in elderly)                              â”‚
â”‚  â”œâ”€â”€ Target Journal: NEJM / Lancet Oncology                                 â”‚
â”‚  â”œâ”€â”€ Timing: Q2 2025 (before competitor ASCO presentation)                  â”‚
â”‚  â”œâ”€â”€ Impact Score: 9.2/10                                                   â”‚
â”‚  â”œâ”€â”€ Evidence Gap Filled: Level 1b for elderly subgroup                     â”‚
â”‚  â””â”€â”€ Value Driver: VD-REV-011 (Market Size) + VD-REV-021 (Value Story)      â”‚
â”‚                                                                             â”‚
â”‚  Priority 2: Real-World Effectiveness Meta-Analysis                         â”‚
â”‚  â”œâ”€â”€ Target Journal: JAMA Network Open                                      â”‚
â”‚  â”œâ”€â”€ Timing: Q3 2025 (aligns with EMA submission)                           â”‚
â”‚  â”œâ”€â”€ Impact Score: 8.5/10                                                   â”‚
â”‚  â”œâ”€â”€ Evidence Gap Filled: Level 2a RWE                                      â”‚
â”‚  â””â”€â”€ Value Driver: VD-RSK-010 (Regulatory) + VD-REV-021 (Value Story)       â”‚
â”‚                                                                             â”‚
â”‚  COMPETITIVE TIMING ANALYSIS                                                â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                                 â”‚
â”‚                                                                             â”‚
â”‚       2025                                                                  â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€           â”‚
â”‚  Jan  Feb  Mar  Apr  May  Jun  Jul  Aug  Sep  Oct  Nov  Dec                 â”‚
â”‚   â”‚    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚                  â”‚
â”‚   â”‚    â”‚    â”‚    â–²ASCO â”‚    â”‚    â–²ESMOâ”‚    â”‚    â”‚    â”‚                      â”‚
â”‚   â”‚    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚                       â”‚
â”‚   â”‚    â–²    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚                       â”‚
â”‚   â”‚ Our Pub â”‚    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚    â”‚                       â”‚
â”‚   â”‚ (before)â”‚    â”‚    â”œâ”€Competitor Xâ”€â”¤    â”‚    â”‚    â”‚                       â”‚
â”‚   â”‚    â”‚    â”‚    â”‚         Phase 3     â”‚    â”‚    â”‚                          â”‚
â”‚                                                                             â”‚
â”‚  RECOMMENDATION: Accelerate subgroup publication to Q1 for first-mover      â”‚
â”‚                  advantage before competitor Phase 3 readout                â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

### Use Case 6: Cross-Functional Strategic Alignment

**Scenario:** Align Medical Affairs, Commercial, and Market Access on evidence strategy.

**VITAL Capability:** Cross-functional JTBD mapping and handoff optimization.

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  CROSS-FUNCTIONAL ALIGNMENT DASHBOARD                                        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                             â”‚
â”‚  FUNCTION ALIGNMENT MAP                                                     â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                                      â”‚
â”‚                                                                             â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”     â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”     â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”       â”‚
â”‚  â”‚ Global Medical  â”‚â”€â”€â”€â”€â–¶â”‚   Commercial    â”‚â”€â”€â”€â”€â–¶â”‚  Market Access  â”‚       â”‚
â”‚  â”‚    Strategy     â”‚     â”‚                 â”‚     â”‚                 â”‚       â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜     â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜     â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜       â”‚
â”‚         â”‚                        â”‚                       â”‚                  â”‚
â”‚         â”‚ Evidence               â”‚ Messaging             â”‚ Value Dossier    â”‚
â”‚         â”‚ Strategy               â”‚ Framework             â”‚ Development      â”‚
â”‚         â”‚                        â”‚                       â”‚                  â”‚
â”‚         â–¼                        â–¼                       â–¼                  â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚                      SHARED JTBD MAPPING                             â”‚   â”‚
â”‚  â”‚                                                                      â”‚   â”‚
â”‚  â”‚  JTBD: "Develop compelling value story for Product X"               â”‚   â”‚
â”‚  â”‚                                                                      â”‚   â”‚
â”‚  â”‚  Medical Strategy Contribution:                                      â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€ Clinical evidence synthesis                                    â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€ KOL validation                                                 â”‚   â”‚
â”‚  â”‚  â””â”€â”€ Publication support                                            â”‚   â”‚
â”‚  â”‚                                                                      â”‚   â”‚
â”‚  â”‚  Commercial Contribution:                                            â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€ Market research integration                                    â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€ Competitive positioning                                        â”‚   â”‚
â”‚  â”‚  â””â”€â”€ Customer insight synthesis                                     â”‚   â”‚
â”‚  â”‚                                                                      â”‚   â”‚
â”‚  â”‚  Market Access Contribution:                                         â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€ HEOR model development                                         â”‚   â”‚
â”‚  â”‚  â”œâ”€â”€ Payer requirement mapping                                      â”‚   â”‚
â”‚  â”‚  â””â”€â”€ Budget impact analysis                                         â”‚   â”‚
â”‚  â”‚                                                                      â”‚   â”‚
â”‚  â”‚  AI-OPTIMIZED HANDOFFS:                                              â”‚   â”‚
â”‚  â”‚  â””â”€â”€ Translation Agent: Medical â†’ Commercial (auto-convert format)  â”‚   â”‚
â”‚  â”‚  â””â”€â”€ Validation Agent: Quality gate before Market Access handoff    â”‚   â”‚
â”‚  â”‚  â””â”€â”€ Coordination Agent: Track status across all three functions    â”‚   â”‚
â”‚  â”‚                                                                      â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                             â”‚
â”‚  ALIGNMENT METRICS                                                          â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                                          â”‚
â”‚  â€¢ Cross-functional meetings reduced: 8 â†’ 2 per major initiative            â”‚
â”‚  â€¢ Handoff cycle time: 36 hours â†’ 8 hours (78% reduction)                   â”‚
â”‚  â€¢ Rework rate: 28% â†’ 8% (71% reduction)                                    â”‚
â”‚  â€¢ Strategic alignment score: 65% â†’ 92%                                     â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## 4. Evidence-Based Decision Framework

### 4.1 Evidence Hierarchy Integration

VITAL integrates a pharmaceutical-specific evidence hierarchy:

| Level | Type | Description | AI Suitability |
|-------|------|-------------|----------------|
| **1a** | Systematic Review/Meta-Analysis | Highest quality synthesis | 92% automatable |
| **1b** | Randomized Controlled Trial | Gold standard for efficacy | 85% automatable |
| **2a** | Systematic Review of Cohort | Observational synthesis | 88% automatable |
| **2b** | Cohort/RWE/PRO Data | Real-world effectiveness | 90% automatable |
| **3a** | Systematic Review of Case-Control | Historical analysis | 85% automatable |
| **3b** | Case-Control Study | Comparative observation | 80% automatable |
| **4** | Case Series | Descriptive evidence | 75% automatable |
| **5** | Expert Opinion/Preclinical | Lowest evidence level | 60% automatable |

### 4.2 Evidence Synthesis Workflow

```python
# AI-Powered Evidence Synthesis Process
evidence_synthesis_workflow = {
    "trigger": "Strategic decision request",
    "steps": [
        {
            "step": "Query Analysis",
            "action": "Parse decision context, identify evidence requirements",
            "output": "Evidence requirement specification"
        },
        {
            "step": "Multi-Source Retrieval",
            "action": "Query Neo4j (ontology) + Pinecone (semantic) + PostgreSQL (structured)",
            "sources": [
                "Clinical trial databases",
                "Publication repositories",
                "Competitive intelligence feeds",
                "Internal knowledge base"
            ]
        },
        {
            "step": "Evidence Grading",
            "action": "Apply evidence hierarchy, score confidence",
            "output": "Graded evidence portfolio"
        },
        {
            "step": "Synthesis Generation",
            "action": "AI-powered narrative synthesis with citations",
            "output": "Executive summary with evidence map"
        },
        {
            "step": "Gap Identification",
            "action": "Compare against decision requirements",
            "output": "Evidence gaps + recommended actions"
        }
    ],
    "quality_gates": [
        "Minimum 3 Level 1-2 sources for major decisions",
        "Confidence score â‰¥ 0.80 for auto-approval",
        "Human review for regulatory implications"
    ]
}
```

### 4.3 Decision Quality Metrics

| Metric | Baseline | VITAL-Enabled | Improvement |
|--------|----------|---------------|-------------|
| Evidence completeness | 60% | 95% | +58% |
| Time to decision | 2 weeks | 3-5 days | -75% |
| Confidence level | Medium | High | +40% |
| Cross-functional alignment | 65% | 92% | +42% |
| Rework/revision rate | 35% | 10% | -71% |

---

## 5. Advanced Analytics & Insights

### 5.1 Predictive Analytics Capabilities

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  PREDICTIVE ANALYTICS SUITE                                                  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                             â”‚
â”‚  1. COMPETITIVE THREAT PREDICTION                                           â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                           â”‚
â”‚  â€¢ Pipeline phase progression forecasting                                   â”‚
â”‚  â€¢ Approval timeline prediction (Â±3 months accuracy)                        â”‚
â”‚  â€¢ Market share impact modeling                                             â”‚
â”‚  â€¢ KOL sentiment trend analysis                                             â”‚
â”‚                                                                             â”‚
â”‚  2. EVIDENCE GENERATION OPTIMIZATION                                        â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                          â”‚
â”‚  â€¢ Publication impact prediction (citation forecast)                        â”‚
â”‚  â€¢ Optimal journal selection (acceptance probability)                       â”‚
â”‚  â€¢ Congress timing optimization                                             â”‚
â”‚  â€¢ KOL authorship network analysis                                          â”‚
â”‚                                                                             â”‚
â”‚  3. MARKET ACCESS INTELLIGENCE                                              â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                              â”‚
â”‚  â€¢ Reimbursement decision prediction by market                              â”‚
â”‚  â€¢ Price elasticity modeling                                                â”‚
â”‚  â€¢ HEOR gap identification                                                  â”‚
â”‚  â€¢ Payer sentiment analysis                                                 â”‚
â”‚                                                                             â”‚
â”‚  4. PORTFOLIO OPTIMIZATION                                                  â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                                  â”‚
â”‚  â€¢ TA investment ROI prediction                                             â”‚
â”‚  â€¢ Resource allocation simulation                                           â”‚
â”‚  â€¢ Pipeline value-at-risk analysis                                          â”‚
â”‚  â€¢ Scenario modeling (bull/base/bear)                                       â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 5.2 Natural Language Query Examples

**For Global Medical Strategy Team:**

| Query Type | Example | AI Response |
|------------|---------|-------------|
| **Evidence Synthesis** | "Summarize all Level 1 evidence for Product X in treatment-naive patients" | Structured synthesis with citations, gaps highlighted |
| **Competitive Analysis** | "How does our evidence portfolio compare to Competitor Y?" | Side-by-side comparison matrix with recommendations |
| **Strategic Planning** | "What evidence do we need to support EU label expansion?" | Prioritized evidence generation roadmap |
| **KOL Intelligence** | "Who are the top 10 KOLs publishing on combination therapy?" | Ranked list with engagement recommendations |
| **Market Access** | "What HEOR data would strengthen our G-BA dossier?" | Gap analysis with specific study recommendations |

### 5.3 Insight Proactive Surfacing

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  PROACTIVE INSIGHT ENGINE                                                    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                             â”‚
â”‚  INSIGHT TYPES:                                                             â”‚
â”‚                                                                             â”‚
â”‚  ğŸ”´ CRITICAL ALERTS (Immediate notification)                                â”‚
â”‚  â€¢ Competitor regulatory approval                                           â”‚
â”‚  â€¢ Safety signal in competitor product                                      â”‚
â”‚  â€¢ Major KOL position change                                                â”‚
â”‚  â€¢ Regulatory guideline update                                              â”‚
â”‚                                                                             â”‚
â”‚  ğŸŸ¡ STRATEGIC OPPORTUNITIES (Daily digest)                                  â”‚
â”‚  â€¢ Evidence gap that competitor hasn't filled                               â”‚
â”‚  â€¢ KOL engagement opportunity                                               â”‚
â”‚  â€¢ Publication timing window                                                â”‚
â”‚  â€¢ Market access pathway change                                             â”‚
â”‚                                                                             â”‚
â”‚  ğŸ”µ TREND INSIGHTS (Weekly summary)                                         â”‚
â”‚  â€¢ Publication volume trends by topic                                       â”‚
â”‚  â€¢ KOL network evolution                                                    â”‚
â”‚  â€¢ Competitive messaging shifts                                             â”‚
â”‚  â€¢ Conference coverage patterns                                             â”‚
â”‚                                                                             â”‚
â”‚  DELIVERY CHANNELS:                                                         â”‚
â”‚  â€¢ Dashboard widgets (real-time)                                            â”‚
â”‚  â€¢ Email digests (configurable frequency)                                   â”‚
â”‚  â€¢ Mobile push notifications (critical only)                                â”‚
â”‚  â€¢ Ask Expert integration (contextual surfacing)                            â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## 6. Value Quantification

### 6.1 ROI Model for Global Medical Strategy

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  VALUE REALIZATION MODEL                                                     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                             â”‚
â”‚  EFFICIENCY GAINS                                                           â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                                            â”‚
â”‚  â€¢ Evidence synthesis: 40 hrs/decision â†’ 8 hrs = 32 hrs saved               â”‚
â”‚  â€¢ Competitive monitoring: 20 hrs/week â†’ 4 hrs = 16 hrs saved               â”‚
â”‚  â€¢ Publication planning: 80 hrs/quarter â†’ 20 hrs = 60 hrs saved             â”‚
â”‚  â€¢ KOL mapping: 60 hrs/update â†’ 10 hrs = 50 hrs saved                       â”‚
â”‚                                                                             â”‚
â”‚  Annual FTE Savings: 6.2 FTE Ã— $150K = $930K                                â”‚
â”‚                                                                             â”‚
â”‚  DECISION QUALITY IMPROVEMENTS                                              â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                              â”‚
â”‚  â€¢ 20% improvement in TA prioritization accuracy                            â”‚
â”‚  â€¢ Portfolio value at $500M â†’ 1% improvement = $5M                          â”‚
â”‚  â€¢ 30% faster response to competitive threats                               â”‚
â”‚  â€¢ Avoided market share loss: 0.5% Ã— $200M = $1M                            â”‚
â”‚                                                                             â”‚
â”‚  Annual Decision Quality Value: $6M                                         â”‚
â”‚                                                                             â”‚
â”‚  RISK REDUCTION                                                             â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                                             â”‚
â”‚  â€¢ 50% reduction in evidence gaps at regulatory submission                  â”‚
â”‚  â€¢ Avoided delay costs: $2M/month Ã— 1 month = $2M                           â”‚
â”‚  â€¢ 40% reduction in publication rejections                                  â”‚
â”‚  â€¢ Saved rework: 15 publications Ã— $50K = $750K                             â”‚
â”‚                                                                             â”‚
â”‚  Annual Risk Reduction Value: $2.75M                                        â”‚
â”‚                                                                             â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•   â”‚
â”‚  TOTAL ANNUAL VALUE: $9.68M                                                 â”‚
â”‚  Implementation Cost (Year 1): $600K                                        â”‚
â”‚  ROI: 16.1x                                                                 â”‚
â”‚  Payback Period: 1.5 months                                                 â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•   â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 6.2 Value Driver Mapping

| JTBD | Primary Value Driver | Impact Magnitude | Annual Value |
|------|---------------------|------------------|--------------|
| TA Prioritization | VD-REV-012 (Market Share) | High (9/10) | $2.5M |
| Evidence Synthesis | VD-CST-010 (Medical Ops) | High (8/10) | $930K |
| Competitive Intelligence | VD-RSK-020 (Market Risks) | High (9/10) | $1.5M |
| KOL Network Optimization | VD-REV-124 (HCP Loyalty) | Medium (7/10) | $800K |
| Publication Strategy | VD-REV-021 (Value Story) | High (8/10) | $1.2M |
| Cross-Functional Alignment | VD-CST-030 (Business Ops) | High (8/10) | $1.0M |

---

## 7. Implementation Playbook

### 7.1 Phase 1: Discovery Sprint (Weeks 1-2)

| Day | Activity | Deliverable |
|-----|----------|-------------|
| 1-2 | Stakeholder interviews (8-10) | Pain point inventory |
| 3 | Discovery workshop (half-day) | Decision inventory, value hypothesis |
| 4-5 | Ontology mapping session | Org structure mapped to L1-L4 |
| 6-7 | JTBD validation interviews | Validated job list with ODI scores |
| 8-9 | Platform demo + use case exploration | Prioritized use case list |
| 10 | Executive readout | Opportunity portfolio + pilot design |

### 7.2 Phase 2: Pilot Execution (Weeks 3-6)

**Recommended Pilot Use Cases:**
1. **Evidence Synthesis** (highest AI suitability, fastest time-to-value)
2. **Competitive Intelligence** (high strategic value, visible ROI)
3. **KOL Network Mapping** (unique platform capability, differentiated)

**Pilot Success Criteria:**
- Time savings â‰¥ 60% vs. baseline
- User satisfaction â‰¥ 8/10
- Evidence completeness â‰¥ 90%
- Adoption rate â‰¥ 70% of pilot users

### 7.3 Phase 3: Scaled Deployment (Weeks 7-12)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  DEPLOYMENT ROADMAP                                                          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                             â”‚
â”‚  Week 7-8: Production Configuration                                         â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                          â”‚
â”‚  â€¢ Agent customization for client therapeutic areas                         â”‚
â”‚  â€¢ Knowledge base integration (internal documents, CI feeds)                â”‚
â”‚  â€¢ SSO and access control setup                                             â”‚
â”‚  â€¢ Dashboard configuration                                                  â”‚
â”‚                                                                             â”‚
â”‚  Week 9-10: User Enablement                                                 â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                              â”‚
â”‚  â€¢ Role-based training (by persona archetype)                               â”‚
â”‚  â€¢ Super-user certification                                                 â”‚
â”‚  â€¢ Self-service documentation                                               â”‚
â”‚  â€¢ Feedback loop implementation                                             â”‚
â”‚                                                                             â”‚
â”‚  Week 11-12: Go-Live + Optimization                                         â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                           â”‚
â”‚  â€¢ Full deployment to Global Medical Strategy team                          â”‚
â”‚  â€¢ Daily monitoring and support                                             â”‚
â”‚  â€¢ Weekly optimization sprints                                              â”‚
â”‚  â€¢ Executive review and expansion planning                                  â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## 8. Success Metrics

### 8.1 KPI Dashboard

| Category | Metric | Baseline | Target | Measurement |
|----------|--------|----------|--------|-------------|
| **Efficiency** | Time to evidence synthesis | 40 hours | 8 hours | Workflow tracking |
| **Efficiency** | Decisions per quarter | 4 | 10 | Decision log |
| **Quality** | Evidence completeness | 60% | 95% | Gap analysis |
| **Quality** | Cross-functional alignment | 65% | 92% | Survey |
| **Adoption** | Active users (weekly) | 0% | 80% | Platform analytics |
| **Adoption** | Queries per user per week | 0 | 15+ | Usage tracking |
| **Value** | Time savings (FTE) | 0 | 6.2 FTE | Time study |
| **Value** | Decision quality improvement | 0% | 20% | Outcome tracking |

### 8.2 Persona-Specific Success Metrics

| Archetype | Primary Metric | Target |
|-----------|---------------|--------|
| **ORCHESTRATOR** | Strategic decisions supported per quarter | 10+ |
| **AUTOMATOR** | Evidence synthesis tasks automated | 80%+ |
| **LEARNER** | Training completion + confidence growth | 90% + 25% |
| **SKEPTIC** | Trust score + adoption rate | 8/10 + 70% |

---

## Appendix A: Glossary

| Term | Definition |
|------|------------|
| **JTBD** | Job-to-be-Done: A specific task or outcome a user needs to accomplish |
| **ODI** | Outcome-Driven Innovation: Scoring methodology (Importance + MAX(Importance - Satisfaction, 0)) |
| **GraphRAG** | Graph-enhanced Retrieval Augmented Generation |
| **L0-L7** | VITAL Ontology layers (Tenant â†’ Workflow) |
| **Value Driver** | Quantifiable business outcome (VD-REV/VD-CST/VD-RSK prefix) |
| **MECE** | Mutually Exclusive, Collectively Exhaustive (persona framework) |

---

## Appendix B: Quick Reference Card

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  VITAL FOR GLOBAL MEDICAL STRATEGY - QUICK REFERENCE                        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                             â”‚
â”‚  KEY USE CASES:                                                             â”‚
â”‚  1. TA Prioritization (85% time reduction)                                  â”‚
â”‚  2. Evidence Gap Analysis (95% completeness)                                â”‚
â”‚  3. Competitive Intelligence (real-time synthesis)                          â”‚
â”‚  4. KOL Network Optimization (graph-based insights)                         â”‚
â”‚  5. Publication Strategy (AI-optimized timing)                              â”‚
â”‚  6. Cross-Functional Alignment (78% faster handoffs)                        â”‚
â”‚                                                                             â”‚
â”‚  VALUE FRAMEWORK:                                                           â”‚
â”‚  â€¢ SMARTER: Better strategic decisions                                      â”‚
â”‚  â€¢ FASTER: 75% time reduction                                               â”‚
â”‚  â€¢ BETTER: 95% evidence completeness                                        â”‚
â”‚  â€¢ EFFICIENT: 6.2 FTE savings                                               â”‚
â”‚  â€¢ SAFER: 50% risk reduction                                                â”‚
â”‚  â€¢ SCALABLE: Enterprise-wide deployment                                     â”‚
â”‚                                                                             â”‚
â”‚  ROI: $9.68M annual value | 16.1x ROI | 1.5 month payback                   â”‚
â”‚                                                                             â”‚
â”‚  CONTACT: [Engagement Team]                                                 â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

**Document Version:** 1.0
**Last Updated:** December 2024
**Maintained By:** VITAL Methodology Team
